| Quarterly Financials | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
Revenue  | 1,345 | 1,612 | 1,709 | 2,229 | 1,574 | 1,777 | 1,814 | 2,196 | 1,802 | 1,980 | 2,034 | 2,591 | 1,993 | 2,320 | 2,233 | 2,812 | 2,031 | 2,124 | 2,193 | 2,811 |
| Expenses | 1,197 | 1,381 | 1,314 | 1,733 | 1,465 | 1,554 | 1,629 | 1,812 | 1,617 | 1,646 | 1,723 | 2,053 | 1,747 | 1,900 | 1,867 | 2,193 | 1,827 | 1,885 | 1,985 | 2,467 |
| EBITDA | 148 | 231 | 395 | 495 | 109 | 223 | 185 | 384 | 185 | 334 | 312 | 538 | 246 | 420 | 367 | 619 | 204 | 239 | 208 | 344 |
| Operating Profit % | 9 % | 12 % | 15 % | 19 % | 1 % | 10 % | 5 % | 16 % | 8 % | 14 % | 12 % | 20 % | 10 % | 15 % | 15 % | 20 % | 6 % | 8 % | 7 % | 10 % |
| Depreciation | 136 | 138 | 147 | 165 | 162 | 166 | 164 | 184 | 174 | 185 | 186 | 196 | 185 | 192 | 197 | 243 | 197 | 203 | 213 | 218 |
| Interest | 42 | 49 | 50 | 57 | 62 | 83 | 95 | 104 | 119 | 110 | 106 | 114 | 107 | 108 | 103 | 104 | 86 | 82 | 89 | 83 |
| Profit Before Tax | -30 | 44 | 198 | 273 | -115 | -26 | -74 | 95 | -107 | 40 | 19 | 228 | -45 | 120 | 67 | 273 | -79 | -46 | -94 | 43 |
| Tax | -2 | 7 | 35 | 69 | -6 | 11 | 17 | 45 | -9 | 35 | 9 | 126 | 44 | 98 | 63 | 119 | 3 | 53 | 42 | 52 |
| Net Profit | -28 | 37 | 163 | 204 | -109 | -37 | -90 | 50 | -99 | 5 | 10 | 101 | -89 | 23 | 4 | 154 | -82 | -99 | -136 | -9 |
| EPS in ₹ | 0.00 | 0.31 | 1.38 | 1.72 | -0.92 | -0.31 | -0.76 | 0.42 | -0.83 | 0.04 | 0.08 | 0.77 | -0.67 | 0.17 | 0.03 | 1.16 | -0.62 | -0.75 | -1.03 | -0.07 |
Piramal Pharma
Piramal Pharma
175.95
+7.66
(4.55%)
Market Cap
23,425.07 Cr
PE Ratio
-68.65
Volume
3,34,16,572.00
Day High - Low
179.25 - 168.10
52W High-Low
220.85 - 132.30
There are new updates from the company1 day ago
View
Key Fundamentals
Market Cap
23,425.07 Cr
EPS
-2.46
PE Ratio
-68.65
PB Ratio
2.74
Book Value
61.34
EBITDA
725.48
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
1.12
Debt to Equity
0.60
Analyst Rating and Forecast
- By Refinitiv from10 analysts
Actual
Company News
View All News
Piramal Pharma files BRSR for FY 2025-26
2 days ago
2 days agoPiramal Pharma Limited filed its Business Responsibility and Sustainability Report for FY 2025-26, disclosing ESG metrics and third-party assurance.
Piramal Pharma reports ₹8,869 Crore revenue in FY2026, posts net loss of ₹325.94 Crore, acquires Kenalog® for USD 35 million, and schedules 6th AGM for July 30, 2026.
Piramal Pharma Limited's promoters have not encumbered any shares during FY 2025-2026, as per SEBI SAST regulations.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,904.80 | #1 4,57,025.33 | 39.02 | #1 58,220.10 | 6.38 | #1 11,565 | 25.80 | 69.58 | |
6,757.00 | 1,79,377.12 | 69.00 | 10,560.00 | 8.73 | 2,520 | 13.44 | 55.41 | |
4,768.30 | 1,61,380.94 | 73.80 | 13,886.20 | 20.34 | 2,138 | -26.91 | 70.39 | |
1,458.20 | 1,17,800.00 | 30.47 | 29,044.60 | 2.24 | 3,870 | -55.32 | 66.80 | |
1,140.60 | 1,14,771.05 | 21.60 | 26,719.70 | 13.65 | 5,242 | 7.82 | 66.88 | |
1,374.10 | 1,14,691.88 | 27.03 | 33,593.30 | -0.44 | 3,998 | -86.05 | 67.04 | |
2,476.00 | 1,13,210.78 | #1 20.48 | 27,487.50 | 19.98 | 5,345 | #1 87.72 | 71.73 | |
2,528.60 | 1,04,430.16 | 53.00 | 14,277.60 | 12.03 | 1,750 | 31.75 | 60.79 | |
1,620.50 | 93,239.99 | 25.87 | 33,384.70 | 3.21 | 3,376 | 1.99 | 70.76 | |
1,542.30 | 83,262.08 | 92.55 | 6,867.80 | #1 22.01 | 890 | 21.18 | 71.63 |
Growth Rate
Revenue Growth
-4.49 %
Net Income Growth
-471.21 %
Cash Flow Change
-11.17 %
ROE
386.96 %
ROCE
22.30 %
EBITDA Margin (Avg.)
-53.32 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 10,900 | 12,797 | 14,523 | 15,312 | 15,678 | 17,965 |
| Fixed Assets | 6,106 | 6,879 | 7,469 | 7,990 | 8,133 | 8,526 |
| Current Assets | 3,649 | 4,067 | 4,836 | 5,465 | 5,797 | 7,192 |
| Capital Work in Progress | 627 | 1,172 | 1,419 | 1,116 | 977 | 799 |
| Investments | 123 | 267 | 639 | 385 | 291 | 3,064 |
| Other Assets | 4,045 | 4,478 | 4,996 | 5,821 | 6,277 | 0 |
| Total Equity & Liabilities | 10,900 | 12,797 | 14,523 | 15,312 | 15,678 | 17,965 |
| Current Liabilities | 2,490 | 3,033 | 3,843 | 4,369 | 3,766 | 4,758 |
| Non Current Liabilities | 2,805 | 3,067 | 3,906 | 3,031 | 3,786 | 5,044 |
| Total Equity | 5,605 | 6,697 | 6,774 | 7,911 | 8,126 | 8,163 |
| Reserve & Surplus | 4,610 | 5,511 | 5,580 | 6,588 | 6,801 | 6,836 |
| Share Capital | 995 | 1,186 | 1,193 | 1,323 | 1,324 | 1,327 |
Cash Flow
| Cash Flow | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 110 | -177 | -32 | 166 | -37 |
| Investing Activities | -4,464 | -1,737 | -1,334 | -416 | -488 |
| Operating Activities | 598 | 766 | 484 | 1,005 | 892 |
| Financing Activities | 3,977 | 794 | 818 | -422 | -441 |
Share Holding
| % Holding | Sept 2022 | Oct 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 34.79 % | 0.00 % | 34.79 % | 34.79 % | 34.79 % | 35.02 % | 35.02 % | 35.02 % | 35.02 % | 34.95 % | 34.95 % | 34.95 % | 34.95 % | 34.86 % | 34.86 % | 34.86 % | 34.86 % |
| FIIs | 20.00 % | 0.00 % | 20.00 % | 20.00 % | 20.00 % | 18.04 % | 32.37 % | 32.51 % | 30.59 % | 31.42 % | 31.73 % | 31.68 % | 31.49 % | 30.86 % | 30.27 % | 29.66 % | 30.18 % |
| DIIs | 4.86 % | 0.00 % | 5.28 % | 4.99 % | 5.49 % | 7.83 % | 8.02 % | 9.68 % | 12.12 % | 12.95 % | 13.81 % | 14.10 % | 14.78 % | 14.26 % | 14.89 % | 15.69 % | 15.61 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 7.42 % | 0.00 % | 11.80 % | 13.94 % | 16.77 % | 16.81 % | 16.95 % | 15.57 % | 15.13 % | 13.94 % | 13.29 % | 13.29 % | 13.11 % | 14.07 % | 14.12 % | 14.11 % | 13.74 % |
| Others | 32.92 % | 100.00 % | 28.14 % | 26.29 % | 22.95 % | 22.30 % | 7.64 % | 7.22 % | 7.14 % | 6.74 % | 6.22 % | 5.98 % | 5.66 % | 5.95 % | 5.86 % | 5.69 % | 5.61 % |
| No of Share Holders | 1,79,957 | 1,79,948 | 2,29,960 | 2,41,359 | 2,77,270 | 2,95,773 | 2,97,225 | 2,92,312 | 2,97,996 | 3,06,398 | 3,59,751 | 4,18,442 | 4,32,843 | 4,58,430 | 4,62,511 | 4,53,830 | 4,50,661 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.56 | 0.00 | 0.11 | 0.14 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.84 | 0.00 | 0.05 | 0.1 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 30 Jul 2026 |  Annual General Meeting | NA | 30 Jul 2026 | 168.20 | 175.95 |
| 02 Aug 2023 |  Rights | 5:46 | 02 Aug 2023 | 101.95 | 103.86 |
| 12 Jul 2024 |  Dividend | ₹ 0.11 /share | 12 Jul 2024 | 148.05 | 151.60 |
| 26 Jul 2024 | Annual General Meeting | NA | 26 Jul 2024 | 157.10 | 166.30 |
| 23 Oct 2024 |  Quarterly Result Announcement | NA | 23 Oct 2024 | 221.30 | 215.15 |
| 28 Jan 2025 | Quarterly Result Announcement | NA | 28 Jan 2025 | 221.25 | 224.00 |
| 14 May 2025 | Quarterly Result Announcement | NA | 14 May 2025 | 214.95 | 214.90 |
| 16 Jul 2025 | Dividend | ₹ 0.14 /share | 16 Jul 2025 | 214.90 | 216.22 |
| 28 Jul 2025 | Quarterly Result Announcement | NA | 28 Jul 2025 | 216.88 | 202.23 |
| 30 Jul 2025 | Annual General Meeting | NA | 30 Jul 2025 | 199.95 | 205.61 |
| 05 Nov 2025 | Quarterly Result Announcement | NA | 05 Nov 2025 | 203.60 | 200.42 |
| 28 Jan 2026 | Quarterly Result Announcement | NA | 28 Jan 2026 | 168.10 | 152.45 |
| 28 Apr 2026 | Quarterly Result Announcement | NA | 28 Apr 2026 | 147.45 | 168.78 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication1 day ago
1 day agoBusiness Responsibility and Sustainability Reporting (BRSR)2 days ago
2 days agoReg. 34 (1) Annual Report.2 days ago
2 days agoNotice Of The 6Th Annual General Meeting And Annual Report For The Financial Year 2025-262 days ago
2 days agoClosure of Trading Window6 days ago
6 days agoClarification On News Item Appearing On NDTV Profit Captioned - "Piramal Pharma Share Price Spikes Over 10% - What Is Driving The Rally?"Jun 23, 2026
Jun 23, 2026Clarification sought from Piramal Pharma LtdJun 23, 2026
Jun 23, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 19, 2026
Jun 19, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 05, 2026
Jun 05, 2026Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 03, 2026
Jun 03, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 01, 2026
Jun 01, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 22, 2026
May 22, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2026
May 19, 2026Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Successful Closure Of US FDA Inspection At Piramal PharmaS Manufacturing Facility Located At Digwal Telangana IndiaMay 18, 2026
May 18, 2026Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 10, 2026
May 10, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 04, 2026
May 04, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeApr 30, 2026
Apr 30, 2026Contact Details Of Key Managerial Personnel As Required Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Apr 29, 2026
Apr 29, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeApr 29, 2026
Apr 29, 2026Announcement under Regulation 30 (LODR)-Change in Registered Office AddressApr 28, 2026
Apr 28, 2026Appointment of Company Secretary and Compliance OfficerApr 28, 2026
Apr 28, 2026Announcement under Regulation 30 (LODR)-CessationApr 28, 2026
Apr 28, 2026Results - Financial Year Ended March 31 2026Apr 28, 2026
Apr 28, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 28, 2026
Apr 28, 2026Announcement under Regulation 30 (LODR)-Investor PresentationApr 28, 2026
Apr 28, 2026Announcement under Regulation 30 (LODR)-Change in DirectorateApr 28, 2026
Apr 28, 2026Announcement under Regulation 30 (LODR)-Change in ManagementApr 28, 2026
Apr 28, 2026Board Meeting Outcome for Outcome Of The Board Meeting Dated April 28 2026Apr 28, 2026
Apr 28, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 17, 2026
Apr 17, 2026Board Meeting Intimation for Considering And Approving The Audited Financial Results (Standalone And Consolidated) Of The Company For Quarter And Financial Year Ended 31St March 2026Apr 17, 2026
Apr 17, 2026Successful Closure Of US FDA Inspection At Piramal PharmaS Manufacturing Facility Located At Lexington USAApr 13, 2026
Apr 13, 2026Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG RatingApr 06, 2026
Apr 06, 2026Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015- Completion Of Acquisition Of Kenalog® A Branded Commercial Injectable ProductApr 01, 2026
Apr 01, 2026Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG RatingsMar 20, 2026
Mar 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 02, 2026
Mar 02, 2026Contact Details Of Key Managerial Personnel As Required Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 24, 2026
Feb 24, 2026Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Revocation Of Closure Direction For CompanyS Dahej SiteFeb 14, 2026
Feb 14, 2026Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - FDA InspectionFeb 14, 2026
Feb 14, 2026Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 11, 2026
Feb 11, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 05, 2026
Feb 05, 2026Announcement under Regulation 30 (LODR)-Change in ManagementFeb 05, 2026
Feb 05, 2026Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 04, 2026
Feb 04, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 30, 2026
Jan 30, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 29, 2026
Jan 29, 2026Appointment of Company Secretary and Compliance OfficerJan 29, 2026
Jan 29, 2026Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerJan 29, 2026
Jan 29, 2026Announcement under Regulation 30 (LODR)-Investor PresentationJan 29, 2026
Jan 29, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 29, 2026
Jan 29, 2026Results - Financial Results For The Quarter Ended December 31 2025Jan 29, 2026
Jan 29, 2026Announcement under Regulation 30 (LODR)-Change in ManagementJan 28, 2026
Jan 28, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 61.20
ATR(14)
Volatile 6.46
STOCH(9,6)
Neutral 59.84
STOCH RSI(14)
Overbought 81.29
MACD(12,26)
Bullish 0.99
ADX(14)
Weak Trend 21.64
UO(9)
Bearish 43.56
ROC(12)
Uptrend And Accelerating 7.50
WillR(14)
Overbought -15.60
About Piramal Pharma
Piramal Pharma Limited is an Indian pharmaceutical company incorporated in 2020. It offers a diverse portfolio of products and services through 17 global facilities and distribution in over 100 countries. The company operates through three main segments: an integrated Contract Development and Manufacturing Organization (CDMO) business, a Complex Hospital Generics...more
Chairperson NameNandini Piramal
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
